Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK9 | P50750 | 18/20 | 0.43 |
| ▸ | CCNT1 | O60563 | 17/20 | 0.43 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.38 |
| ▸ | BTK | Q06187 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL16962704 | 0.99 | CDK9 (0.42) | CDK9CCNT1PRMT5BTK | |
| Hydrochloric Acid SCHEMBL5002137 | 0.99 | CDK9 (0.42) | CDK9CCNT1PRMT5BTK | |
| Trifluoroacetic Acid SCHEMBL5008133 | 0.92 | BTK (0.41) | CDK9CCNT1PRMT5BTK | |
| SCHEMBL13996682 | 0.89 | CDK9 (0.41) | CDK9CCNT1PRMT5BTK | |
| SCHEMBL13994535 | 0.89 | BTK (0.41) | CDK9CCNT1BTK | |
| Hydrochloric Acid SCHEMBL5005426 | 0.88 | BTK (0.41) | CDK9CCNT1BTK | |
| Hydrochloric Acid SCHEMBL5004769 | 0.88 | BTK (0.41) | CDK9CCNT1BTK | |
| Hydrochloric Acid SCHEMBL5005421 | 0.87 | CDK9 (0.42) | CDK9CCNT1BTK | |
| Triaziquone SCHEMBL17063658 | 0.86 | CDK9 (0.35) | CDK9CCNT1PRMT5BTK | |
| SCHEMBL5001882 | 0.82 | MKNK1 (0.58) | CDK9CCNT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150252047-A1 | SUBSTITUTED INDAZOL-PYRROLOPYRIMIDINES USEFUL IN THE TREATMENT OF HYPERPROLIFERATIVE DISEASES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-09-10 | — | — | US | claimed |
| EP-2900670-A1 | SUBSTITUTED INDAZOL-PYRROLOPYRIMIDINES USEFUL IN THE TREATMENT OF HYPERFOLIFERATIVE DISORDERS | Bayer Pharma Aktiengesellschaft (DE) | 2015-08-05 | — | — | EP | claimed |
| EP-2900671-A1 | SUBSTITUTED INDAZOL-PYRROLOPYRIMIDINES USEFUL IN THE TREATMENT OF HYPERPROLIFERATIVE DISEASES | Bayer Pharma Aktiengesellschaft (DE) | 2015-08-05 | — | — | EP | claimed |
| US-20150252047-A1 | SUBSTITUTED INDAZOL-PYRROLOPYRIMIDINES USEFUL IN THE TREATMENT OF HYPERPROLIFERATIVE DISEASES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-09-10 | — | — | US | disclosed |
| US-20150218173-A1 | SUBSTITUTED INDAZOL-PYRROLOPYRIMIDINES USEFUL IN THE TREATMENT OF HYPERFOLIFERATIVE DISORDERS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-08-06 | — | — | US | disclosed |
| EP-2900671-A1 | SUBSTITUTED INDAZOL-PYRROLOPYRIMIDINES USEFUL IN THE TREATMENT OF HYPERPROLIFERATIVE DISEASES | Bayer Pharma Aktiengesellschaft (DE) | 2015-08-05 | — | — | EP | disclosed |
| EP-2900670-A1 | SUBSTITUTED INDAZOL-PYRROLOPYRIMIDINES USEFUL IN THE TREATMENT OF HYPERFOLIFERATIVE DISORDERS | Bayer Pharma Aktiengesellschaft (DE) | 2015-08-05 | — | — | EP | disclosed |
| US-7465726-B2 | Substituted pyrrolo[2.3-B]pyridines | OSI PHARMACEUTICALS, INC. (US) | 2008-12-16 | — | — | US | disclosed |
| US-7465726-B2 | Substituted pyrrolo[2.3-B]pyridines | OSI PHARMACEUTICALS, INC. (US) | 2008-12-16 | — | — | US | disclosed |
| US-7465726-B2 | Substituted pyrrolo[2.3-B]pyridines | OSI PHARMACEUTICALS, INC. (US) | 2008-12-16 | — | — | US | disclosed |
| CN-101052629-A | Aryl-amino substituted pyrrolopyrimidine multi-kinase inhibiting compounds | OSI PHARM INC (US) | 2007-10-10 | — | — | CN | disclosed |
| US-20060211678-A1 | Aryl-amino substituted pyrrolopyrimidine multi-kinase inhibiting compounds | OSI PHARMACEUTICALS, INC. | 2006-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211678-A1 | Aryl-amino substituted pyrrolopyrimidine multi-kinase inhibiting compounds | BMX, ERBB2, FRK | CDK9 428/4885CCNT1 1580/4885PRMT5 709/4885 |
| US-20150218173-A1 | SUBSTITUTED INDAZOL-PYRROLOPYRIMIDINES USEFUL IN THE TREATMENT OF HYPERFOLIFERATIVE DISORDERS | CCND2, ARG2, ARG1 | CDK9 647/4885CCNT1 20/4885PRMT5 324/4885 |
| US-20150252047-A1 | SUBSTITUTED INDAZOL-PYRROLOPYRIMIDINES USEFUL IN THE TREATMENT OF HYPERPROLIFERATIVE DISEASES | CCND2, CCND1, CCNA1 | CDK9 91/4885CCNT1 10/4885PRMT5 255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.